[August 10, 2012]

Research and Markets: Triple Analysis: Lung Cancer, Apoptosis and Protein Kinase Inhibitors - 2012 Out Now

Research and Markets (http://www.researchandmarkets.com/research/6h9rxl/triple_analysis_l) has announced the addition of the "Triple Analysis: Lung Cancer, Apoptosis and Protein Kinase Inhibitors" report to their offering.

This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Lung Cancer

This part is based on the following publication: Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Reserch To Market

Part II: Apoptosis

This part is based on the following publication: Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Protein Kinase Inhibitors

Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Supporting development of integrative molecule, pathway and disease area strategies

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

For more information visit http://www.researchandmarkets.com/research/6h9rxl/triple_analysis_l

[ Back To Financial Technology's Homepage ]